FindTrial
Sign In

Clinical Application and Efficacy Analysis of Lymphoplasma Exchange in Severe Drug Eruptions

Clinical Application and Efficacy Analysis of Lymphoplasma Exchange in Severe Drug Eruptions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113967
Enrollment
Unknown
Registered
2025-12-04
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe drug rash

Interventions

The non-lymphoplasmapheresis group:None
The lymphoplasmapheresis group:None

Sponsors

Guangxi Zhuang Autonomous Region People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with severe drug eruptions

Exclusion criteria

Exclusion criteria: 1. Exclude patients with hemodynamic instability (requiring ECMO support); 2. Severe cardiopulmonary dysfunction; 3. Severe bone marrow suppression; 4. Patients discharged within 3 days of admission, etc.

Design outcomes

Primary

MeasureTime frame
The time for rash regression;—

Secondary

MeasureTime frame
Complication rate;mortality rate;Inflammatory factor levels;length of hospital stay;—

Countries

China

Contacts

Public ContactZeng Yanting

Guangxi Zhuang Autonomous Region People's Hospital

214269663@qq.com+86 771 218 6134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026